Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 401,175
  • Shares Outstanding, K 57,475
  • Annual Sales, $ 61,880 K
  • Annual Income, $ -105,540 K
  • 60-Month Beta 1.00
  • Price/Sales 6.89
  • Price/Cash Flow N/A
  • Price/Book 1.68
Trade STRO with:

Options Overview Details

View History
  • Implied Volatility 98.68% ( +27.64%)
  • Historical Volatility 66.69%
  • IV Percentile 50%
  • IV Rank 32.30%
  • IV High 303.38% on 05/11/22
  • IV Low 1.04% on 05/09/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 61
  • Put/Call OI Ratio 2.18
  • Today's Open Interest 1,470
  • Open Int (30-Day) 1,181

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.75
  • Number of Estimates 6
  • High Estimate -0.62
  • Low Estimate -0.93
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +9.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.78 +3.03%
on 10/31/22
8.37 -16.59%
on 11/21/22
-0.25 (-3.46%)
since 10/28/22
3-Month
5.05 +38.35%
on 09/23/22
8.37 -16.59%
on 11/21/22
+1.02 (+17.11%)
since 08/26/22
52-Week
3.33 +109.61%
on 06/16/22
17.70 -60.56%
on 11/30/21
-9.20 (-56.86%)
since 11/26/21

Most Recent Stories

More News
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%

The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable,...

STRO : 6.98 (-5.93%)
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

STRO : 6.98 (-5.93%)
TELA : 8.41 (-1.06%)
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STRO : 6.98 (-5.93%)
HSKA : 60.49 (-2.67%)
GSK (GSK) Q3 Earnings and Revenues Beat Estimates

Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK : 33.76 (-0.68%)
STRO : 6.98 (-5.93%)
Why Investors Are Suddenly Excited About Vaxcyte

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

PCVX : 44.03 (+0.07%)
PFE : 49.57 (+0.73%)
MRNA : 175.38 (-0.58%)
STRO : 6.98 (-5.93%)
MRK : 108.45 (+0.88%)
Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable,...

STRO : 6.98 (-5.93%)
Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable,...

STRO : 6.98 (-5.93%)
bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.

BLUE : 7.37 (-2.90%)
SESN : 0.5350 (-1.27%)
ARDS : 0.9499 (+5.54%)
STRO : 6.98 (-5.93%)
Axsome (AXSM) Initiates Late-Stage Alzheimer's Agitation Study

Axsome Therapeutics (AXSM) enrolls the first patient in a late-stage study of AXS-05 for Alzheimer's disease agitation.

AXSM : 74.74 (+31.54%)
SESN : 0.5350 (-1.27%)
STRO : 6.98 (-5.93%)
IMCR : 58.95 (-4.21%)
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

VBLT : 0.1530 (+3.38%)
AXSM : 74.74 (+31.54%)
STRO : 6.98 (-5.93%)
IMCR : 58.95 (-4.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 8.02
2nd Resistance Point 7.78
1st Resistance Point 7.38
Last Price 6.98
1st Support Level 6.74
2nd Support Level 6.51
3rd Support Level 6.11

See More

52-Week High 17.70
Fibonacci 61.8% 12.21
Fibonacci 50% 10.52
Fibonacci 38.2% 8.82
Last Price 6.98
52-Week Low 3.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar